Findings

What do systematic reviews say?

6 questions · 6 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 16.7%Low 3 · 50%Moderate 2 · 33.3%High 0 · 0%

Number of ocular adverse events at the longest · people with primary open‐angle glaucoma or ocular hypertension

1 finding from 1 review

Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1131 participants
Low

Number of ocular adverse events at the longest · people with primary open‐angle glaucoma or ocular hypertension

1 finding from 1 review

Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1678 participants
Moderate

Number of ocular adverse events at the longest · people with primary open‐angle glaucoma or ocular hypertension

1 finding from 1 review

Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1286 participants
Low

Average number of ocular adverse events at the longest · people with primary open‐angle glaucoma or ocular hypertension

1 finding from 1 review

Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 188 participants
Very low

Number of ocular adverse events at the longest · people with primary open‐angle glaucoma or ocular hypertension

1 finding from 1 review

Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 208 participants
Moderate

Number of ocular adverse events at the longest · people with primary open‐angle glaucoma or ocular hypertension

1 finding from 1 review

Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1321 participants
Low